Table 1.

Characteristics of the patients at baseline.

NBL 280 mg/m2/dose
CharacteristicsValue(n = 20)
Age at enrollment (years)Median (min, max)5 (2, 14)
Sex
Female7 (35%)
Male13 (65%)
Race
White18 (90%)
Black1 (5%)
Asian1 (5%)
Unknown0 (0%)
No. of prior therapies
1–23 (15%)
3–45 (25%)
5–64 (20%)
7+8 (40%)
No. of patients with at least one prior therapy
Chemotherapy19 (95%)
Radiotherapy16 (80%)
Transplant11 (55%)
Surgery15 (75%)
Immunotherapy5 (25%)
Prior therapy NOS9 (45%)
Disease status
Evaluable7 (35%)
Measurable13 (65%)
Cohort
Phase I6 (30%)
Phase II14 (70%)
ALK Aberration
Amplification2 (10%)
Arg1275Gln12 (60%)
Arg1275Gln; Phe1174Leu1 (5%)
Phe1174Leu3 (15%)
Phe1174Val1 (5%)
Tyr1278Ser1 (5%)